ACXP

Acurx Pharmaceuticals' stock has experienced a significant decline over the past six months. Key events impacting the stock price include the Q4 2025 earnings report, which announced a net loss despite beating analyst EPS expectations, an anticipated delay in FDA approval for ibezapolstat, and presentations and business updates. The company announced its Q4 2025 earnings, reporting a net loss of $1.6 million for the quarter and $8.0 million for the full year 2025. Alliance Global reportedly slashed its price target on Acurx due to pushing back the expected FDA approval of ibezapolstat for C. difficile infection to 2031 from 2028. The company has announced scientific poster presentations and plans to present at healthcare company showcases and investor summits in April and May 2026.